GPCR · Structure Therapeutics Inc. · Executive Compensation

$21.19 -0.74 (-3.37%) At close · Oct 23

Market Cap

$1.51B

71.31M

Volume · Oct 23 798.11K Avg daily vol (3M) 1.06M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Raymond Stevens	Chief Executive Officer and Director	$672,094	—	$2,387,996	$4,846,926	$508,871	$14,000	$8,429,887
Jun Yoon	Chief Financial Officer	$530,530	—	$1,193,998	$2,423,463	$309,075	$10,529	$4,467,595
Blai Coll	M.D., Ph.D. Chief Medical Officer	$492,813	—	$820,866	$1,666,117	$253,151	$14,000	$3,246,947
Xichen Lin	Chief Scientific Officer	$505,313	—	$567,150	$1,151,143	$257,103	—	$2,480,709
Yingli Ma	Chief Technology Officer	$429,768	—	$447,734	$908,788	$212,592	—	$1,998,882

Fiscal 2024

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Raymond Stevens	Chief Executive Officer and Director	$634,246	—	$1,582,514	$3,173,843	$334,447	$13,800	$5,738,850
Xichen Lin	Chief Scientific Officer	$476,542	—	$1,007,057	$2,019,700	$185,799	$1,668	$3,690,766
Blai Coll	M.D., Ph.D. Chief Medical Officer	$449,138	—	$1,296,452	$1,504,500	$187,150	$13,800	$3,451,040
Jun Yoon	Chief Financial Officer	$482,300	—	$698,761	$1,401,433	$217,068	$13,800	$2,813,362

Fiscal 2023

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Raymond Stevens	Chief Executive Officer and Director(4)	$595,852	—	—	$6,500,534	$281,325	$13,200	$7,390,911
Jun Yoon	Chief Financial Officer	$441,262	—	—	$3,047,125	$173,183	$13,200	$3,674,770
Mark Bach	M.D., Ph.D. Chief Medical Officer	$485,812	—	—	—	$173,045	$13,200	$672,057

Fiscal 2022

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Raymond Stevens	Chief Executive Officer and Director(4)	$487,333	—	—	—	$247,500	$12,500	$747,333
Mark Bach	M.D., Ph.D. Chief Medical Officer	$466,375	—	—	—	$149,499	$12,500	$628,374

Executive changes

Person	Role	Change	Effective	Filed
Matthew Lang	Chief Operating Officer and General Counsel	Appointed	2026-04-15	2026-04-15
Matthew Lang	Chief Operating Officer and General Counsel	Appointed	2026-04-15	2026-04-15
Ashley Hall, J.D.	Chief Development Officer	Appointed	2024-09-18	2024-09-17
Blai Coll, M.D., Ph.D.	Chief Medical Officer	Appointed	2024-09-18	2024-09-17
Mark Bach, M.D., Ph.D.	Chief Medical Officer	Resigned	2024-09-18	2024-09-17
Angus Russell	Class I director	Appointed	2024-08-26	2024-08-27
Ted Love, M.D.	Class III director	Appointed	2023-08-03	2023-08-04

Leadership

Raymond Stevens CEO, Board Member
Jun Yoon CFO
Matthew Lang COO, General Counsel
Yingli Ma CTO
Angus Russell Board Member
Ted Love, M.D. Board Member

Key facts CIK 1888886 CUSIP 86366E106 13F (30d) 14 filings 14 filers Visit website Investor relations